Maraviroc for treatment-naive patients with HIV-1 infection: Is the glass half empty or half full?

Journal of Infectious Diseases

Volumn 201, Issue 6, 2010, Pages 797-799

  Sax, Paul E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; VIRUS RNA;

CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; TRIAZOLES;

EID: 77749268003     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650701     Document Type: Note

References (20)

1. Moyle GJ, Wildfire A, Mandalia S, et al. Ep-idemiology and predictive factors for che-mokine receptor use in HIV-1 infection. J In-fect Dis 2005; 191:866-872. (Pubitemid 40349800)
2. Brumme Z, Goodrich J, Mayer H, et al. Mo- lecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiret-roviral-naive individuals. J Infect Dis 2005; 192:466-474. (Pubitemid 41023125)
3. Cooper DA, Heera J, Goodrich J, et al; for the MERIT Study Team. Maraviroc versus efavi-renz, both in combination with zidovudine-lamivudine, for the treatment of antiretrovi-ral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010;201:803-813 (in this issue).
4. Panel on Antiretroviral Guidelins for Adults and Adolescents. Guidelines for the use of an-tiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1 December 2009; 1-161. Available at: http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Ac-cessed 22 January 2010.
5. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV In-fection: 2008 recommendations of the In-ternational AIDS Society-USA Panel. JAMA 2008;300(5):555-570.
6. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, Moyle G. The impact of HIV tro-pism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008;46(10):1617-1623. (Pubitemid 351706746)
7. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing pheno-type for rate of CD4+ cell depletion and pro-gression to AIDS. Ann Intern Med 1993; 118: 681-688. (Pubitemid 23118038)
8. Fätkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008;359:1442-1455.
9. Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection; a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008; 197: 262-265. (Pubitemid 351263445)
10. Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008; 197:183-186.
11. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treat-ment-experienced patients: AIDS Clinical Tri-als Group 5211. J Infect Dis 2007; 196(2): 304-312.
12. Trinh L, Han D, Huang W, et al. Technical Validation of an enhanced sensitivity Trafile HIV coreceptor tropism assay for selecting pa-tients for therapy with entry inhibitors tar-geting CCR5. Antivir Ther 2008; 13(suppl 3): A128.
13. DeJesus E, Walmsley S, Cohen C, et al. Fasted lipid changes after administration of maravi-roc or efavirenz in combination with zido-vudine and lamivudine (Combivir) for 48 weeks to treatment-naive HIV-infected pa-tients. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunis-tic Infections. 2008. Abstract 929.
14. Alirezaei M, Watry D, Flynn C, et al. HIV-1/ surface glycoprotein 120 induces apoptosis through RNA-activated protein kinase signal-ling in neurons. J Neurosci 2007; 27:11047-11055.
15. Funderburg N, Kalinowska M, Eason J, et al. Differential effects of maraviroc (MVC) and efavirenz (EFV) on markers of immune ac-tivation (IA) and inflammation and their as-sociation with CD4 cell rises: a subanalysis of the MERIT study. In: Program and abstracts of the 49th Interscience Conference on An-timicrobial Agents and Chemotherapy. 2009. Abstract H-1582.
16. Lanzafame M, Lattuada E, Vento S. Maraviroc and CD4+ cell count recovery in patients with virologie suppression and blunted CD4R cell response. AIDS 2009; 23:869.
17. Stepanyuk O, Chiang T, Dever L, et al. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but im-paired CD4 recovery. AIDS 2009; 23:1911-1913.
18. Dumond JB, Patterson KB, Pecha AL, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative wom-en. J Acquir Immune Defic Syndr 2009; 51(5): 546-553.
19. Fletcher PS, Herrera C, Armanasco N, et al. Anti-HIV activity of the candidate microbicide maraviroc, a CCR5 receptor antagonist. In: Program and abstracts of the 5th IAS Con-ference on HIV Pathogenesis, Treatment and Prevention. 2009. Abstract WEPDC201.
20. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5delta32/delta32 stem cell transplantation. N Engl J Med 2009; 360:692-698.